Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by AB Science
AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement
Today 2:28 EDT
From
AB Science
Via
GlobeNewswire
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024
September 23, 2024
From
AB Science
Via
GlobeNewswire
AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19
July 08, 2024
From
AB Science
Via
GlobeNewswire
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
June 28, 2024
From
AB Science
Via
GlobeNewswire
AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
May 31, 2024
From
AB Science
Via
GlobeNewswire
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
May 29, 2024
From
AB Science
Via
GlobeNewswire
AB Science reports its revenues for the year 2023 and provides an update on its activities
May 15, 2024
From
AB Science
Via
GlobeNewswire
AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036
May 13, 2024
From
AB Science
Via
GlobeNewswire
AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient
May 07, 2024
From
AB Science
Via
GlobeNewswire
AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science
May 02, 2024
From
AB Science
Via
GlobeNewswire
AB Science announces a slight delay in the publication of its 2023 annual financial report
April 30, 2024
From
AB Science
Via
GlobeNewswire
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
March 13, 2024
From
AB Science
Via
GlobeNewswire
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
March 07, 2024
From
AB Science
Via
GlobeNewswire
AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
March 06, 2024
From
AB Science
Via
GlobeNewswire
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
March 01, 2024
From
AB Science
Via
GlobeNewswire
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
February 29, 2024
From
AB Science
Via
GlobeNewswire
AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
February 26, 2024
From
AB Science
Via
GlobeNewswire
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
January 26, 2024
From
AB Science
Via
GlobeNewswire
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
January 15, 2024
From
AB Science
Via
GlobeNewswire
AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
November 27, 2023
From
AB Science
Via
GlobeNewswire
AB Science today reports its revenues for the first half of 2023 and provides an update on its activities
September 29, 2023
From
AB Science
Via
GlobeNewswire
AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS
September 18, 2023
From
AB Science
Via
GlobeNewswire
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)
June 26, 2023
From
AB Science
Via
GlobeNewswire
AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037
June 01, 2023
From
AB Science
Via
GlobeNewswire
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit
May 17, 2023
From
AB Science
Via
GlobeNewswire
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter
May 09, 2023
From
AB Science
Via
GlobeNewswire
AB Science reports its revenues for the year 2022 and provides an update on its activities
April 28, 2023
From
AB Science
Via
GlobeNewswire
AB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting
April 27, 2023
From
AB Science
Via
GlobeNewswire
AB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037
April 18, 2023
From
AB Science
Via
GlobeNewswire
AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline
April 12, 2023
From
AB Science
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.